Compare RENX & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | ICU |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.5M |
| IPO Year | 2023 | 2021 |
| Metric | RENX | ICU |
|---|---|---|
| Price | $0.96 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 81.9K | ★ 199.6K |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,220,449.00 | $1,234,000.00 |
| Revenue This Year | $109.28 | $72.04 |
| Revenue Next Year | $53.56 | $38.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3860.67 | 814.07 |
| 52 Week Low | $0.84 | $0.22 |
| 52 Week High | $203.14 | $5.38 |
| Indicator | RENX | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 38.73 | 30.94 |
| Support Level | $0.89 | N/A |
| Resistance Level | $2.16 | $3.53 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 28.29 | 21.59 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.